Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
3.900
+0.080 (2.09%)
Oct 31, 2025, 4:00 PM EDT - Market closed
Cytek Biosciences Revenue
Cytek Biosciences had revenue of $45.60M in the quarter ending June 30, 2025, a decrease of -2.18%. This brings the company's revenue in the last twelve months to $196.04M, down -0.85% year-over-year. In the year 2024, Cytek Biosciences had annual revenue of $200.45M with 3.85% growth.
Revenue (ttm)
$196.04M
Revenue Growth
-0.85%
P/S Ratio
2.56
Revenue / Employee
$302,523
Employees
648
Market Cap
496.17M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 200.45M | 7.44M | 3.85% |
| Dec 31, 2023 | 193.02M | 28.98M | 17.67% |
| Dec 31, 2022 | 164.04M | 36.09M | 28.20% |
| Dec 31, 2021 | 127.95M | 35.11M | 37.82% |
| Dec 31, 2020 | 92.84M | 34.96M | 60.39% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2009 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
CTKB News
- 2 days ago - Cytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry - GlobeNewsWire
- 9 days ago - Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025 - GlobeNewsWire
- 16 days ago - Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth - GlobeNewsWire
- 6 weeks ago - Cellares Selects Five Best-in-Class Technology Providers, Tecan, Advanced Instruments, Cytek Biosciences, Slingshot Biosciences and AltemisLab, to Expand Cell Q's Capabilities in Meeting Demands for Commercial Scale Cell Therapy Quality Control - Business Wire
- 7 weeks ago - Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA - GlobeNewsWire
- 7 weeks ago - Cytek Biosciences, Inc. (CTKB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 2 months ago - Cytek Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Cytek Biosciences, Inc. (CTKB) Q2 2025 Earnings Call Transcript - Seeking Alpha